RoslinCT
Bronze
Information
CDMO established in 2006 and among the first to produce clinical-grade hPSCs and supporting the commercialization of CRISPR-edited stem cell-based therapy. With 22 purpose-built cGMP processing suites, it provides PD/AD, cGMP clinical and commercial manufacturing for cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
Contact Phone: +44 (0) 131 376 9926
Booth Number
22
